{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:35:10Z","timestamp":1793230510344,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>\n                    Although not registered for feline infectious peritonitis (FIP) in Japan, nucleoside analogs have shown efficacy and we have been offering them to owners of cats with FIP at our clinic since January 2020. The aim of this study was to investigate outcomes in cats with FIP who received GS-441524 or molnupiravir. Diagnosis of FIP was based on clinical signs, laboratory test results, and the presence of feline coronavirus RNA in blood or effusion aspirate. After providing verbal and written information, owners of cats with a presumptive diagnosis of FIP with a were offered antiviral treatment with commercially sourced GS-441524 from June 2020, and either GS-441524 or compounded molnupiravir from January 2022. Dosing was 12.5\u201325\u2009mg\/kg\/day for GS-441524 and 20\u201340\u2009mg\/kg\/day for molnupiravir, depending on the presence of effusion and neurological and\/or ocular signs, and continued for 84\u2009days. Overall, 118 cats with FIP (effusive in 76) received treatment, 59 with GS-4421524 and 59 with molnupiravir. Twenty cats died, 12\/59 (20.3%) in the GS-441524 group and 8\/59 (13.6%) in the molnupiravir group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.326), with most deaths within the first 10\u2009days of starting treatment. Among survivors, neurological and ocular signs resolved in all but one cat, who had persistent seizures. Of the cats completing treatment, 48\/48 in the GS-441524 group and 51\/52 in the molnupiravir group achieved remission. Laboratory parameters normalized within 6 to 7\u2009weeks of starting drug administration. Adverse events, such as primarily hepatic function abnormalities, were transient and resolved without specific intervention. Our data indicate that GS-441524 and molnupiravir show similar effects and safety in cats with FIP.\n                  <\/jats:p>","DOI":"10.3389\/fvets.2024.1422408","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:51:35Z","timestamp":1721263895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["GS-441524 and molnupiravir are similarly effective for the treatment of cats with feline infectious peritonitis"],"prefix":"10.3389","volume":"11","author":[{"given":"Okihiro","family":"Sase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Iwami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.cvsm.2011.08.004","article-title":"Feline coronavirus in multicat environments","volume":"41","author":"Drechsler","year":"2011","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jfms.2008.09.008","article-title":"A review of feline infectious peritonitis virus infection: 1963-2008","volume":"11","author":"Pedersen","year":"2009","journal-title":"J Feline Med Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tvjl.2014.04.016","article-title":"An update on feline infectious peritonitis: diagnostics and therapeutics","volume":"201","author":"Pedersen","year":"2014","journal-title":"Vet J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/v15091847","article-title":"Feline infectious peritonitis: European advisory board on cat diseases guidelines","volume":"15","author":"Tasker","year":"2023","journal-title":"Viruses"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/01652176.2020.1845917","article-title":"Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats","volume":"40","author":"Izes","year":"2020","journal-title":"Vet Q"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/pathogens10091150","article-title":"Feline coronavirus antivirals: a review","volume":"10","author":"Delaplace","year":"2021","journal-title":"Pathogens"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.rvsc.2020.02.012","article-title":"Oral Mutian(R)X stopped faecal feline coronavirus shedding by naturally infected cats","volume":"130","author":"Addie","year":"2020","journal-title":"Res Vet Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/jvim.16803","article-title":"Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524","volume":"37","author":"Coggins","year":"2023","journal-title":"J Vet Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/v15081680","article-title":"Efficacy of Oral Remdesivir compared to GS-441524 for treatment of cats with naturally occurring effusive feline infectious peritonitis: a blinded, non-inferiority study","volume":"15","author":"Cosaro","year":"2023","journal-title":"Viruses"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/jvim.16804","article-title":"Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524","volume":"37","author":"Green","year":"2023","journal-title":"J Vet Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ani11082257","article-title":"Unlicensed GS-441524-like antiviral therapy can be effective for at-home treatment of feline infectious peritonitis","volume":"11","author":"Jones","year":"2021","journal-title":"Animals (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/vetsci8120328","article-title":"Therapeutic effects of Mutian((R)) Xraphconn on 141 client-owned cats with feline infectious peritonitis predicted by Total bilirubin levels","volume":"8","author":"Katayama","year":"2021","journal-title":"Vet Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/vetsci10020136","article-title":"Prognostic prediction for therapeutic effects of Mutian on 324 client-owned cats with feline infectious peritonitis based on clinical laboratory indicators and physical signs","volume":"10","author":"Katayama","year":"2023","journal-title":"Vet Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/v13112228","article-title":"Curing cats with feline infectious peritonitis with an Oral multi-component drug containing GS-441524","volume":"13","author":"Krentz","year":"2021","journal-title":"Viruses"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/v14051069","article-title":"Fecal feline coronavirus RNA shedding and spike gene mutations in cats with feline infectious peritonitis treated with GS-441524","volume":"14","author":"Meli","year":"2022","journal-title":"Viruses"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1098612x19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J Feline Med Surg"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1098612X231194460","DOI":"10.1177\/1098612X231194460","article-title":"Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022)","volume":"25","author":"Taylor","year":"2023","journal-title":"J Feline Med Surg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1098612X231183250","DOI":"10.1177\/1098612X231183250","article-title":"Long-term follow-up of cats in complete remission after treatment of feline infectious peritonitis with oral GS-441524","volume":"25","author":"Zwicklbauer","year":"2023","journal-title":"J Feline Med Surg"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2460\/javma.23.08.0466","article-title":"Unlicensed antiviral products used for the at-home treatment of feline infectious peritonitis contain GS-441524 at significantly different amounts than advertised","volume":"262","author":"Kent","year":"2024","journal-title":"J Am Vet Med Assoc"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2460\/ajvr.23.10.0221","article-title":"Quality assessment and characterization of unregulated antiviral drugs for feline infectious peritonitis: implications for treatment, safety, and efficacy","author":"Mulligan","year":"2024","journal-title":"Am J Vet Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/jvim.16832","article-title":"Molnupiravir treatment of 18 cats with feline infectious peritonitis: a case series","volume":"37","author":"Sase","year":"2023","journal-title":"J Vet Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/1098612X18809165","article-title":"Diagnosis of non-effusive feline infectious peritonitis by reverse transcriptase quantitative PCR from mesenteric lymph node fine-needle aspirates","volume":"21","author":"Dunbar","year":"2019","journal-title":"J Feline Med Surg"},{"key":"ref23","year":"2023"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/pathogens11101209","article-title":"Unlicensed Molnupiravir is an effective rescue treatment following failure of unlicensed GS-441524-like therapy for cats with suspected feline infectious peritonitis","volume":"11","author":"Roy","year":"2022","journal-title":"Pathogens"},{"key":"ref25","volume-title":"The long history of Beta-d-N4-hydroxycytidine and its modern application to treatment of Covid-19 in people and FIP in cats [online]","author":"Pedersen","year":"2021"},{"key":"ref26","year":"2021"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/v14112429","article-title":"An optimized bioassay for screening combined Anticoronaviral compounds for efficacy against feline infectious peritonitis virus with pharmacokinetic analyses of GS-441524, Remdesivir, and Molnupiravir in cats","volume":"14","author":"Cook","year":"2022","journal-title":"Viruses"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.88092","article-title":"Microcrystalline cellulose as pharmaceutical excipient","volume-title":"Pharmaceutical Formulation Design-Recent Practices","author":"Chaerunisaa","year":"2020"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1422408\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:51:39Z","timestamp":1721263899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2024.1422408\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":28,"alternative-id":["10.3389\/fvets.2024.1422408"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2024.1422408","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"article-number":"1422408"}}